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A B S T R A C T
A missense C1858T single nucleotide polymorphism within PTPN22 is a strong genetic risk factor for the de-
velopment of multiple autoimmune diseases. PTPN22 encodes a protein tyrosine phosphatase that negatively
regulates immuno-receptor proximal Src and Syk family kinases. Notably, PTPN22 negatively regulates kinases
downstream of T-cell receptor (TCR) and LFA-1, thereby setting thresholds for T-cell activation. Alterations to
the quality of TCR and LFA-1 engagement at the immune synapse and the regulation of downstream signals can
have profound effects on the type of effector T-cell response induced. Here we describe how IFNγ+ Th1 re-
sponses are potentiated in Ptpn22−/− T-cells and in T-cells from mice expressing Ptpn22R619W (the mouse or-
thologue of the human genetic variant) as they age, or following repeated immune challenge, and explore the
mechanisms contributing to the expansion of Th1 cells. Specifically, we uncover two LFA-1-ICAM dependent
mechanisms; one T-cell intrinsic, and one T-cell extrinsic. Firstly, we found that in vitro anti-CD3/LFA-1 induced
Th1 responses were enhanced in Ptpn22−/− T-cells compared to WT, whereas anti-CD3/anti-CD28 induced IFNy
responses were similar. These data were associated with an enhanced ability of Ptpn22−/− T-cells to engage
ICAM-1 at the immune synapse when incubated on planar lipid bilayers, and to form conjugates with dendritic
cells. Secondly, we observed a T-cell extrinsic mechanism whereby repeated stimulation of WT OT-II T-cells with
LPS and OVA323-339 pulsed Ptpn22−/− bone marrow derived dendritic cells (BMDCs) was sufficient to enhance
Th1 cell development compared to WT BMDCs. Furthermore, this response could be reversed by LFA-1 blockade.
Our data point to two related but distinct mechanisms by which PTPN22 regulates LFA-1 dependent signals to
enhance Th1 development, highlighting how perturbations to PTPN22 function over time to regulate the balance
of the immune response.
1. Introduction
The non-synonymous PTPN22 polymorphism C1858T (encoding
R620W) is a strong risk factor for the development of multiple auto-
immune diseases, including rheumatoid arthritis (RA), type I diabetes,
systemic lupus erythematosus, and juvenile idiopathic arthritis [1].
PTPN22 encodes a tyrosine phosphatase that negatively regulates Src
and Syk family kinase (SFK) activity downstream of immuno-receptor
signalling cascades [2]. It has become apparent that PTPN22 regulates
many pathways in different cell types including the T-cell receptor [3],
B-cell receptor [4], integrins [5], as well as dectin-1 [6] and Toll-Like
Receptor (TLR) signalling pathways [7–10]. While it has become widely
accepted that the autoimmune associated PTPN22R620W variant displays
reduced binding to the negative regulatory tyrosine kinase Csk due to a
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missense mutation in the P1 domain [2,11], our understanding as to
precisely how the R620W variant affects PTPN22 function remains in-
complete. Gain- and loss-of-phosphatase function effects have been
reported for the R620W variant, depending on the cellular context and
signalling pathway being investigated [5,10–12].
In the peripheral secondary lymphoid organs, Ptpn22−/− mice ex-
hibit homeostatic expansion of CD4+ and CD8+ effector T-cells [3].
Expansion occurs post-thymic selection in an age dependent manner,
and is considered to be caused primarily by the TCR being hyper-re-
sponsive to antigen stimulation [1]. Furthermore, PTPN22 has a greater
impact on the regulation of effector/memory T-cell responses, rather
than naïve T-cells, and this is most evident when Ptpn22−/− T-cells are
engaged by MHC molecules presenting lower affinity peptide antigens
or low avidity anti-CD3/anti-CD28 stimulation, resulting in enhanced
T-cell Ca2+ flux and proliferation [13,14]. In addition to regulating T-
cell proliferation, the quality of TCR signalling also determines effector
T-cell responses, and perturbations to these pathways are capable of
exerting profound effects on the type of immune response initiated
[15]. Indeed, multiple studies have observed that, by modulating TCR
signalling thresholds, PTPN22 negatively regulates the expansion of
peripheral regulatory T-cells [14], and is also capable of modulating
Th17 to Th1/Treg switching [16]. Therefore, alterations to PTPN22, as
conferred by PTPN22R620W may impact both the quantity and quality of
T-cell immune responses, thereby conferring increased risk of auto-
immunity.
Previous investigations have demonstrated that PTPN22 is dis-
pensable for Th1 generation in vitro in response to CD3 and CD28 sti-
mulation [14]. However, in addition to CD3 and CD28, the integrin
LFA-1 also participates in immune synapse stabilisation, and engage-
ment of LFA-1 via ICAM-1 contributes to costimulatory signals trans-
duced in T cells [17]. Our recent investigations have revealed that
PTPN22 negatively regulates LFA-1 signalling and T-cell adhesion [5].
Furthermore, multiple studies have demonstrated that LFA-1 engage-
ment is a potent inducer of IFNγ+ expression during Th1 cell induction
[18,19]. Here, we present data indicating that PTPN22 operates in both
a T-cell intrinsic and extrinsic manner to negatively regulate LFA-1
dependent induction of Th1 cells.
2. Methods
2.1. Mice
Wild type (WT) C57BL/6, Ptpn22−/−, Ptpn22R619W and OT-II TCR
transgenic mice were maintained under specific pathogen free (SPF)
conditions and used in experiments according to UK Home Office ap-
proved protocols. Ptpn22−/− mice and Ptpn22R619W mutant mice were
backcrossed for more than 10 generations to the C57BL/6 strain. Their
generation and genotyping have been previously described in detail
[4,20]. Age and gender-matched mice were used at either 2–4 month
or> 12 months in all experiments, as indicated.
2.2. Induction and assessment of collagen induced arthritis
The induction of collagen induced arthritis (CIA) in the C57BL/6
strain was performed as previously published [17]. Male WT and
Ptpn22−/− mice of 10–14 weeks of age were injected intradermally at
the base of the tail with 100 μg chicken type II collagen (Sigma)
emulsified in complete Freund's adjuvant. Clinical signs of arthritis
were assessed visually in the wrist and ankle joints 3 times weekly,
using a previously described severity scale: 0= no arthritis; 1= 1 in-
flamed digit; 2= 2 inflamed digits; 3=more than 2 digits and footpad
inflamed; 4= all digits and footpad inflamed [17]. Scoring was con-
ducted under blinded conditions for up to 96 days. At day 96 single cell
suspensions from lymph nodes (LN) and spleens were restimulated for
6 h with PMA (Sigma; 50 ng/ml) ionomycin (Sigma; 10 ng/ml) and
monensin (Biolegend; 1 in 1000) and expression of IFNγ (clone
XMG1.2; Biolegend), IL-17 (clone TC11-18H10.1; Biolegend), TNFα
(clone MP6-XT22; Biolegend), IL-4 (clone 11B11; Biolegend) and IL-10
(clone JES5-16E3; Biolegend) determined by intracellular flow cyto-
metry.
2.3. Total CD4 and naïve CD4+ T-cell isolation
Naïve CD4+CD44− T-cells from the LNs and spleens of WT and
Ptpn22−/− mice were selected using MACS naïve CD4+ negative se-
lection kit according to manufacturer's instructions (Miltenyi Biotech).
Total CD4+ T-cells from the lymph nodes (LN) and spleens of WT OT-II
mice were isolated using CD4+ MACS negative selection kit according
to manufacturer's instructions (Miltenyi Biotech). Purity of naïve
CD4+CD62L+ T-cells and total CD4+ T-cells was determined by flow
cytometry to be routinely 90–95%.
2.4. Differentiation of primary naïve or total CD4+ T cells
Naïve CD4+ CD44lo CD62L+ T-cells or total CD4+ T-cells were
resuspended in RPMI-1640 with L-glutamine supplemented with 10%
heat-inactivated FBS, β-mercaptoethanol (50 μM), penicillin/strepto-
mycin (100 μg/ml), HEPES (10mM) and plated at 1× 106 cells/ml in
48 well flat-bottomed tissue culture plates coated overnight with anti-
CD3 (0–2 μg/ml; Biolegend) in the presence or absence of ICAM-1-Fc
(0–2 μg/ml; Biolegend). Naïve T-cells were cultured in the presence of
soluble anti-CD28 (2 μg/ml; Biolegend) and IL-2 (20 ng/ml) for Th0
conditions, or IL-2 (20 ng/ml), IL-12 (20 ng/ml; Peprotech) and anti-IL-
4 (10 μg/ml; Biolegend) for Th1 polarising conditions. IL-2 was added
to the culture medium every 48 h to achieve a final concentration of
10 ng/ml. Total CD4+ T-cells were cultured at 1×106 cells/ml in 96-
well flat-bottom plates in the presence or absence of IL-12 (20 ng/ml)
and anti-IL-4 (10 μg/ml) for Th1. On day 3 half the media was removed
and cells were transferred to a new 96-well plate and media refreshed
with IL-2 (20 ng/ml). CD4+ T-cell cultures were maintained for 5 days,
at which point intracellular cytokine staining for cytokines was per-
formed.
2.5. Bone marrow derived dendritic cell (BMDC) culture
BMDC were produced using a protocol adapted from Inaba et al.
[21]. Bone marrow was flushed from femurs and tibias of WT and
Ptpn22−/− mice with RPMI-1640 supplemented with L-glutamine
(Corning) containing 1% FBS and penicillin/streptomycin (100 μg/ml).
Bone marrow cells were incubated in Petri dishes for 30min at 37 °C in
5% CO2 to remove adherent macrophages. Non-adherent progenitor
cells were seeded at 1.5× 106 cells/ml in 24-well tissue culture plates
in RPMI-1640 with L-glutamine supplemented with 10% heat-in-
activated FBS, β-mercaptoethanol (50 μM), penicillin/streptomycin
(100 μg/ml) and 1% murine GM-CSF; GM-CSF was produced from the
B78H1/GMCSF.1 cell line. BMDC were cultured for 6 days at 37 °C and
5% CO2 and medium was partially replenished on day 3 and fully re-
placed on day 4. BMDCs were used in functional assays on days 6 and 7.
Cells were harvested by washing with PBS containing 2mM EDTA. At
day 6 WT and Ptpn22−/− immature DC generated were routinely>
90% CD11c+ determined by flow cytometry.
2.6. BMDC phenotype
BMDCs were harvested and stained using anti-mouse CD11c (clone
N418; Biolegend), anti-mouse CD11b (clone M1/70; Biolegend), MHC
class II I-Ab (clone AF6-120.1; Biolegend), CD86 (clone GL-1;
Biolegend), CD40 (clone 3/23; Biolegend), and Zombie Fixable
Viability dye (Biolegend) in PBS containing anti-mouse CD16/CD32
(clone 93; Biolegend). Cells were washed with FACS buffer (5% FBS,
1mM EDTA, 0.01% NaN3 in PBS) and fixed using 1% paraformalde-
hyde (PFA, Electron Microscopy Services) in FACS buffer.
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2.7. In vitro co-cultures
WT and Ptpn22−/− BMDC were matured overnight in the presence
of soluble LPS from E. coli at 100 ng/ml (Invivogen). Mature BMDCs
were pulsed with OVA323-339 (Invivogen) at 1 μg/ml for 4 h at 37 °C.
BMDC were harvested, washed and resuspended in RPMI-1640 with L-
glutamine supplemented with 10% heat-inactivated FBS, β-mercap-
toethanol (50 μM), penicillin/streptomycin (100 μg/ml). CD4+ OT-II T-
cells were isolated and 2× 107 cells/ml were labelled with 2 μM
CellTrace Violet (CTV, Invitrogen) for 20min at 37 °C. BMDC were co-
cultured with CTV labelled CD4+ T-cells at a BMDC:T-cell ratio of 1:2
(5× 104 BMDC:1×105 T-cells) in 96-well round bottom plates for 6
days. On the sixth day of co-culture, 100 μl of complete RPMI was re-
moved and freshly pulsed BMDCs of the same original genotype were
added to the culture for a further 48 h (day 8). Proliferation and in-
tracellular cytokine production by OT-II T cells were assessed by flow
cytometry and soluble cytokine production determined by im-
munoassay on days 6 and 8.
2.8. Cytokine immunoassays and cell phenotyping
Cell-free co-culture supernatants were harvested at the indicated
times. IL-2 and IFNγ were determined by immunoassay. Antibody pairs
were purchased from Biolegend. Cytokine levels were determined using
streptavidin-europium and enhancement solution (both from Perkin
Elmer) and detected on a Victor 1420 multilabel counter (Perkin
Elmer). Day 1 or 6 BMDC and OT-II T-cell co-cultures were harvested
and stained with anti-CD3ε-FITC (clone 145.2C11; Biolegend), anti-
CD4-PerCP (clone RM4-5; Biolegend), anti-CD69 (clone H1.2F3;
Biolegend), anti-CD25 (PC61; Biolegend) and Fixable Viability Dye
eFluor 506(eBiosciences). Cells were fixed in 1% PFA in PBS.
Proliferating and activated T-cell populations were determined by
gating on live, singlet, CD3+, CD4+ cells and by CTV dilution.
2.9. Planar supported lipid bilayers
For microscopy CD4+ T-cells (1× 106 cells/ml) were activated for
2 days with mouse anti-CD3/anti-CD28 Dynabeads (1× 106 beads/ml;
Invitrogen) in the presence of 20 ng/ml IL-2. On day 2 beads were
magnetically removed and T-cells rested in media in the presence of
20 ng/ml IL-2 for a further 4–6 days. Lipid bilayers were prepared as
previously described [22]. 25×75-mm glass coverslips were cleaned
with Piranha solution (Cyantek Corporation) and adhered to sticky-
Slides VI0.4 (Ibidi). Liposomes containing 0.01mol% biotin-CAP-
phosphatidylethanolamine, 97.49% mol% phosphatidylcholine, and
2.5 mol% Ni2+-chelating lipids (Avanti Polar Lipids) were placed in to
the chambers to form planar bilayers. After blocking for 30min with
5% casein, 100 μM NiCl2, followed by 30min with fluorescently la-
belled mouse ICAM-1-12His (200 molecules/μm2), and unlabelled
streptavidin (5 μg/ml, Sigma), and 30min with mono-biotinylated Fab'
fragments of mouse anti-CD3ε antibodies (5 μg/ml) were added to the
chambers. The UCHT1 density was 30 molecules/μm2. Flow chambers
were warmed to 37 °C and cells added for the indicated time points,
prior to fixing with 2% PFA at room temperature for 20min.
2.10. Microscopy
Total internal reflection fluorescence (TIRF) microscopy imaging
was performed on an Olympus IX83 motorized TIRF microscopy with a
150×/1.45 NA objective and an Andor IXON ULTRA 512X512 EMCCD
camera. For each cell the mean intensity of CD3 and ICAM-1 was cal-
culated by dividing the total fluorescence intensity of the region of
interest (ROI) minus background fluorescence of a neighbouring area
(measured using the same ROI) and then divided by the area of the ROI.
2.11. DC-T cell conjugate assay
LPS (Invivogen; 100 ng/ml) matured WT BMDCs pulsed with
OVA323-339 (1 μg/ml) were used to activate WT or Ptpn22−/− T-cells for
6 days. On day 6 a fresh preparation of LPS matured, OVA323-339 pulsed
(1 μg/ml) WT BMDC were harvested, washed and resuspended at
1× 107 cells/ml prior to staining with 2 μM CellTrace Far Red (CTFR,
Invitrogen). Day 6 activated T-cells were harvested and resuspended at
2× 107 cells/ml prior to staining with 1 μM CellTrace Violet (CTV,
Invitrogen). Staining was performed for 20min at 37 °C, followed by
quenching in culture media for 20min at 37 °C. 5×104 CTFR labelled
WT BMDCs and 1×105 CTV labelled WT or Ptpn22−/− OT-II CD4+ T-
cells (in a total volume of 50 μl) were added to 1.5ml tubes, centrifuged
for 2min at 500 rpm and incubated at 37 °C for the indicated times.
Cells were fixed with 3% PFA in PBS for 15min at room temperature,
transferred to FACS tubes and acquired by flow cytometry using a
medium flow rate. Conjugates were identified as CTV+ CTFR+ cells.
2.12. Flow cytometry
Gates were determined by fluorescence minus one (FMO) controls.
Cells were acquired using Becton Dickinson Fortessa or FACSCanto II
flow cytometers, and data analysed using FlowJo Version 8.7.
2.13. Statistical analysis
GraphPad Prism software was used for statistical analysis by un-
paired, paired T-test, one-way, or two-way ANOVA with Sidak's post-
test (paired or unpaired; two-tails). In arthritis experiments, the area
under the curve (AUC) was computed and compared between geno-
types by Mann Whitney U test. P values less than 0.05 were considered
significant.
3. Results
3.1. Th1 effector cells preferentially accumulate in lymphoid organs of
Ptpn22−/− and Ptpn22619W mice
In vivo, lymphoid organs of Ptpn22−/− and Ptpn22619W mice display
an age dependent expansion of CD4+ CD44hi CD62Llo effector/memory
T-cells and CD4+ CD25+ FoxP3+ regulatory T cells (Tregs) [3,20]. We
hypothesised that PTPN22 also regulates the cytokine producing cap-
ability of in vivo CD4+ T-cells. We first assessed the capability of CD4+
T-cells from the lymphoid organs of young (< 4 months) and aged
(> 12 months) WT and Ptpn22−/− mice to produce IFNγ, IL-4, IL-17,
and TNFα. As previously reported, Ptpn22−/− mice exhibited age de-
pendent expansion of CD25+Foxp3+ regulatory T-cells compared to
WT controls (Supplementary Fig. 1A), while WT and Ptpn22−/− CD4+
T-cells from mice< 4 months had similar frequencies of IFNγ, IL-17,
TNFα and IL-4 producing cells (Fig. 1A, Supplementary Fig. 1B). In
comparison, although the frequency of IFNγ+ CD4+ T cell was in-
creased in aged mice regardless of genotype, aged Ptpn22−/− mice
displayed a significantly expanded population of IFNγ+ CD4+ T-cells in
both the lymph nodes and spleens (Fig. 1A and Supplementary Fig. 1B).
Furthermore, mice expressing Ptpn22W619 (the murine orthologue of the
human autoimmune associated variant) also displayed a significant age
dependent increase in the frequency of IFNγ producing CD4+ T-cells
compared to Ptpn22R619 (WT) aged-matched controls (Fig. 1B). Ptpn22
mediated expansion of IFNγ+ T-cells appeared specific to IFNγ, as no
significant Ptpn22 dependent changes to the frequencies of IL-17, IL-4
or TNFα+ CD4+ T cells were observed in either young or aged mice
(Fig. 1A and B).
We next assessed if immune challenge of young mice in the context
of the collagen induced arthritis (CIA) model was sufficient to re-
produce differences in IFNγ+ T-cell frequencies according to genotype.
Ninety-six days after arthritis induction, spleens and lymph nodes of
C. Sanchez-Blanco et al. Journal of Autoimmunity 94 (2018) 45–55
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WT and Ptpn22−/− mice were pooled and assessed for IFNγ+ CD4+ T-
cells. Following immune challenge, Ptpn22−/− mice preferentially ac-
cumulate IFN-γ producing CD4+ T cells when compared to WT
(Fig. 1C). Again, we observed that loss of PTPN22 specifically mediated
the expansion of IFNγ+ CD4+ T-cells as no significant changes were
observed in IL-17, and TNFα frequencies. In this CIA model, Ptpn22−/−
mice also developed a visible, yet non-significant, increase in paw
swelling compared to WT mice (Fig. 1D). Together, these results suggest
that, with aging, or in response to immune challenge, IFNγ+ T-cells
preferentially accumulate in Ptpn22−/− and Ptpn22619W mice.
3.2. PTPN22 does not regulate CD3 and CD28 mediated IFNγ production
We next sought to investigate in vitro the pathways regulated by
PTPN22 that might account for expansion of IFNγ+ T-cells in vivo.
Multiple T-cell intrinsic and extrinsic factors regulate the capability of
CD4+ T cells to produce IFNγ and differentiate into Th1 cells. First, we
assessed if PTPN22 was capable of regulating naïve CD4+ T-cell dif-
ferentiation towards a Th1 phenotype in a T-cell intrinsic manner. To
address this question WT and Ptpn22−/− CD4+ naïve T cells were sti-
mulated under polarising conditions in the presence of anti-CD3 and
anti-CD28, with IL-2 alone (Th0) or IL-2 with IL-12 and anti-IL-4 (Th1).
At day six following restimulation with PMA and ionomycin, we ob-
served that under both Th0 (Fig. 2A) or Th1 (Fig. 2B) polarising con-
ditions there was no difference in the proportion of IFNγ, IL-10, IL-4, IL-
17, or TNFα+ T-cells generated from naïve WT or Ptpn22−/− T-cells.
Previous investigations have revealed that PTPN22 regulates TCR sig-
nalling thresholds, and that reduced TCR signal strength, conferred by
low affinity antigen, enhances IFNγ production by CD8+ T-cells [13].
As such we assessed if reduced levels of anti-CD3 stimulation would
reveal differences in the capability of naïve Ptpn22−/− T-cells to pro-
duce IFNγ. However, titrating anti-CD3 revealed no significant differ-
ences between the frequency of IFNγ+ T-cells generated from WT or
Ptpn22−/− naïve CD4+ T-cells (Fig. 2C). Since loss of PTPN22 function
predominantly effects the activation of effector/memory T-cells rather
than naïve T-cells, we assessed if the differentiation of total (naïve and
effector/memory) CD4+ T-cells towards a Th1 phenotype would be
altered in Ptpn22−/− mice. Total CD4+ T-cells were stimulated with a
Fig. 1. Ptpn22−/− and Ptpn22R619W mice accumulate Th1 cells with age or following chronic immune challenge. Skin draining lymph nodes of< 4month
(Young) and>12-month-old (Aged) (A) WT and Ptpn22−/− mice or (B) WT and Ptpn22R619W were assessed for intracellular IFNγ, IL-16, TNFα, and IL-4 cytokine
production following 6 h PMA, Ionomycin and monensin stimulation, determined by intracellular flow cytometry. N= 4–5 mice per genotype/time point. (C, D) For
collagen induced arthritis model WT and Ptpn22−/− mice were immunised with CII in CFA (immunised) and compared to unimmunised mice (control). (C) Day 96
lymph nodes were restimulated for 6 h with PMA, ionomycin and monensin for 6 h and expression of IFNγ, IL-17, and TNFα determined by intracellular flow
cytometry. (D)Mean clinical score of WT and Ptpn22−/− immunised mice 0–96 days. N = 10 mice/group; bars represent mean + s.e.m. (A–C) Each point represents
an individual mouse, bars represent mean ± s.e.m.; NS = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-way ANOVA, applying
Sidak's multiple comparisons test.
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range of plate bound anti-CD3 concentrations (0.03–2 μg/ml) in the
presence of soluble anti-CD28, anti-IL-4 and IL-12. However, even at
reduced anti-CD3 concentrations no PTPN22 dependent differences
were observed in the frequency of IFNγ+ CD4 T-cells or the secretion of
IFNγ (Fig. 2D–F). When culturing total CD4+ T-cells under IFNγ po-
larising conditions we observed a very high frequency of IFNγ+ cells
(Fig. 2F, 60–80%), we therefore sought to exclude the possibility that
the presence of IL-12 was masking a PTPN22 mediated regulation of
anti-CD3/anti-CD28 stimulation induced IFNγ by performing the cul-
tures in the absence of IL-12. However, despite the reduced frequency
of IFNγ+ cells generated in the absence of IL-12, no PTPN22 dependent
differences in the expansion of IFNγ+ CD4+ T-cells was observed
(Fig. 2G–I). These data indicate that PTPN22 does not negatively reg-
ulate CD3/CD28 mediated differentiation of IFNγ+ CD4 T-cells.
3.3. PTPN22 negatively regulates ICAM-1-LFA-1 dependent T-cell synapse
formation and IFNγ secretion
LFA-1 is a potent costimulatory molecule capable of enhancing TCR
dependent IFNγ secretion by T-cells [17]. PTPN22 acts as a negative
regulator of LFA-1 dependent signalling, adhesion and migration
[5,20]. We therefore sought to determine whether LFA-1 mediated
expansion of IFNγ+ T-cells was regulated by PTPN22. WT or Ptpn22−/
− CD4+ T-cells were stimulated with plate bound anti-CD3 and a range
of ICAM-1-Fc concentrations (0–2 μg/ml) for 3 or 5 days in the presence
(Fig. 3A–C) or absence of IL-12 (Fig. 3D–F). In the presence of IL-12 we
again observed no difference in the capability of WT or Ptpn22−/− T-
cells to secrete IFNγ (Fig. 3A–C). Interestingly however, in the absence
of IL-12 we observed that Ptpn22−/− T-cells had an enhanced cap-
ability to secrete IFNγ in comparison to WT T-cells over multiple ICAM-
Fig. 2. PTPN22 does not regulate CD3 and CD28 mediated IFNγ production (A, B)WT and Ptpn22−/− naïve CD4+ T-cells were stimulated via plate bound anti-
CD3 and soluble anti-CD28 under (A) Th0 (IL-2) and (B) Th1 (IL-12, IL-2 and anti-IL-4) polarising conditions. Day 5 T-cells were restimulated for 6 h with PMA,
ionomycin and monensin and the proportion of CD3+ CD4+ IFNγ+, IL-17+, IL-4+, TNFα+, or IL-10+ cells determined by intracellular flow cytometry. N=3
independent experiments per genotype (C) WT and Ptpn22−/− naïve T-cells were stimulated via plate bound anti-CD3 (0.001–0.5 μg/ml) and soluble anti-CD28
(2 μg/ml) under Th1 polarising conditions. (D–F) Total WT and Ptpn22−/− CD4+ T-cells were stimulated via plate bound anti-CD3 (0.03–2 μg/ml) and soluble anti-
CD28 (2 μg/ml) under Th1 polarising conditions. Cell free supernatants at (D) day 3 and (E) day 5 were assessed for IFNγ by ELISA. (F) Day 5 T-cells were
restimulated for 6 h with PMA, ionomycin and monensin and the proportion of CD3+ CD4+ IFNγ+ cells determined by intracellular flow cytometry. (G–I) Total WT
and Ptpn22−/− CD4+ T-cells were stimulated with plate bound anti-CD3 (2 μg/ml) and soluble anti-CD28 (2 μg/ml) under non-polarising conditions. Cell free
supernatants at (G) day 3 and (H) day 5 were assessed for IFNγ by ELISA. (I) Day 5 T-cells were restimulated for 6 h with PMA, ionomycin and monensin and the
proportion of CD3+ CD4+ IFNγ+ cells determined by intracellular flow cytometry. (A-I) N=3–5 per group with each data point representing T-cells isolated from an
individual mouse, bars represent mean ± s.e.m.; NS= not significant determined by un-paired T-test.
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1 concentrations (Fig. 3D–E). Previous investigations have noted that
LFA-1 stimulation predominantly regulates T-cell secretion of IFNγ ra-
ther than intracellular expression of IFNγ [18]. Our data supports this
as more IFNγ was detected from Ptpn22−/− cell cultures by ELISA,
whereas the proportion of IFNγ+ cells was unchanged (Fig. 3D–F), in
contrast to anti-CD3/anti-CD28 stimulation which modulated neither
IFNγ secretion nor intracellular expression (Fig. 2D–F). We previously
observed that Ptpn22−/− T-cells display enhanced phosphorylation of
multiple kinases downstream of LFA-1 [5], which may account for the
increased LFA-1 mediated IFNγ secretion in Ptpn22−/− T-cells. LFA-1
(caption on next page)
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function is controlled by both affinity and avidity [23] following TCR
mediated inside-out signalling. The TCR accumulates at the centre of
the immunological synapse in extracellular vesicles that activate an-
tigen-presenting cells [24]. LFA-1 forms a ring of densely packed
clusters that engage ICAM-1 and mediate dynamic adhesion [25]. Over
time we observed that Ptpn22−/− CD4+ T-cells incubated on planar
supported lipid bilayers containing anti-CD3 and ICAM-1 displayed an
enhanced density of ICAM-1 at the immune synapse compared to WT T-
cells, indicative of enhanced LFA-1 interaction with ICAM-1 in
Ptpn22−/− T cells (Fig. 3G and H). By contrast densities of anti-CD3
were not affected. To further test the functional effects of enhanced
LFA-1/ICAM-1 interactions during immune synapse formation, we ex-
amined T cell-DC conjugate formation. Within 10min Ptpn22−/− T-
cells were capable of forming more conjugates with WT BMDC, as
compared to WT T-cells (Fig. 3I and J). We conclude that enhanced
LFA-1 responsiveness, manifested by increased densities of LFA-1-
ICAM-1 at the immune synapse and enhanced conjugate formation,
could be responsible for the expansion of IFNγ+ T-cells.
3.4. PTPN22 regulates the capability of BMDC to induce Th1 responses
In vivo antigen presenting cells (APCs) mediate the activation and
differentiation of T-cells. Recent investigations have revealed a role for
PTPN22 in DC activation [6,7,10,26]. We therefore assessed if PTPN22
might also regulate the expansion of Th1 responses by modulating APC
mediated T-cell activation. Bone marrow derived dendritic cells
(BMDCs) from WT and Ptpn22−/− mice were generated with GM-CSF
and matured overnight with LPS prior to pulsing for the final 4 h with
OVA323-339. In contrast to previously described data, Ptpn22 was not
found to influence the maturation of either immature or LPS matured
BMDCs (Supplementary Fig. 3A) [10]. Matured WT or Ptpn22−/−
BMDC were co-cultured with CTV labelled WT CD4+ OT-II cells for 6
days and then T-cells re-challenged for a further 48 h with a fresh
preparation of LPS and OVA323-339 pulsed BMDC of the same WT or
Ptpn22−/− genotype. We compared the capability of the WT and
Ptpn22−/− LPS matured BMDCs to induce OT-II T-cell proliferation and
inflammatory cytokine production. Although no difference in T-cell
proliferation was noted (Supplementary Fig. 3B), we found that sti-
mulation with Ptpn22−/− BMDCs significantly enhanced the proportion
of IFNγ+ OT-II T-cells compared to OT-II cells co-cultured with WT
BMDCs (Fig. 4A). Furthermore, as observed in vivo the effects of T-cell
co-culture with Ptpn22−/− BMDC appeared to be specific to IFNγ
production, as IL-17 responses were not dependent on BMDC PTPN22
expression (Fig. 4A). In addition, we found that lacking Ptpn22 in both
BMDC and in CD4+ OT-II T-cells also resulted in enhanced Th1 re-
sponses, though the proportion of IFNγ+ cells was not further po-
tentiated beyond that of Ptpn22−/− BMDC co-cultured with WT OT-II
T-cells (Fig. 4B). These data indicate that enhanced Th1 responses ob-
served in Ptpn22−/− mice may also be in part dependent on an en-
hanced capability of APCs to induce Th1 activation.
3.5. Ptpn22−/− BMDC do not regulate Th1 responses via altered cytokine
secretion
To explore how Ptpn22−/− BMDC were capable of inducing en-
hanced Th1 responses we assessed if LPS stimulation of WT and
Ptpn22−/− BMDC resulted in differing Th1 skewing cytokine profiles.
IL-12 is known to promote Th1 responses and previous investigations
Fig. 3. PTPN22 negatively regulates ICAM-1-LFA-1 dependent T-cell synapse formation and IFNγ secretion. (A–C) WT and Ptpn22−/− CD4+ T-cells were
stimulated via plate bound anti-CD3 and ICAM-1-Fc in the presence of IL-12 and anti-IL-4. Cell free supernatants at (A) day 3 and (B) day 5 were assessed for IFNγ by
ELISA. (C) Day 5 T-cells were restimulated for 6 h with PMA, ionomycin and monensin and the proportion of CD3+ CD4+ IFNγ+ cells determined by intracellular
flow cytometry. (D–F) WT and Ptpn22−/− CD4+ T-cells were stimulated via plate bound anti-CD3 and ICAM-1-Fc in the presence of anti-IL-4 but the absence of IL-
12. Cell free supernatants at (D) day 3 and (E) day 5 were assessed for IFNγ by ELISA. (F) Day 5 T-cells were restimulated for 6 h with PMA, ionomycin and monensin
and the proportion of CD3+ CD4+ IFNγ+ cells determined by intracellular flow cytometry. (G, H) Immune synapse formation by WT and Ptpn22−/− CD4+ T-cells
following incubation on planar supported lipid bilayers containing anti-CD3 and ICAM-1. (G) representative example of CD3 and ICAM-1 distribution over time
within a WT T-cell immune synapse. (H) For each cell the mean intensity of CD3 and ICAM-1 was calculated by dividing the total fluorescence intensity of the region
of interest (ROI, shown by yellow outline) by the area of the ROI.> 50 cells/group, representative of> 3 independent experiments. Bars represent mean
****p < 0.0001 by one-way ANOVA. (I, J) Conjugates were formed between activated CTV labelled WT and Ptpn22−/− OT-II CD4+ T-cells and CFTR labelled
OVA323-339 pulsed WT BMDC. CTV+CFTR+ conjugates were determined by flow cytometry at 0 and 10min at 37 °C. (I) representative flow cytometry plots,
quantified in (J) percentage of CD4+ T-cells in conjugates. N = 4–5 independent experiments per group. Bars represent mean ± s.d; NS = not significant,
*p < 0.05, **p < 0.01 by two-way ANOVA, applying Sidak's multiple comparisons test. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
Fig. 4. Ptpn22−/− BMDC are able to promote Th1 responses. (A) Day 6 WT
and Ptpn22−/− LPS and OVA323-339 pulsed BMDC were co-cultured with WT
CD4+ OT-II T-cells for 6 days. At day 6, T-cells were restimulated with a fresh
preparation of WT or Ptpn22−/− BMDC for 48 h and then restimulated for 6 h
with PMA, ionomycin and monensin and the proportion of CD3+ CD4+ IFNγ+
or IL-17+ cells was determined by intracellular flow cytometry. (B) Day 6 WT
and Ptpn22−/− LPS and OVA323-339 pulsed BMDC were co-cultured with
Ptpn22−/− CD4+ OT-II T-cells for 6 days. At day 6 T-cells were restimulated
with a fresh preparation of WT or Ptpn22−/− BMDC and then restimulated for
6 h with PMA, ionomycin and monensin and the proportion of CD3+ CD4+
IFNγ+ or IL-17+ cells determined by intracellular flow cytometry. N=6–7 per
group with each data point representing an individual WT or Ptpn22−/− BMDC
preparation, points are paired by the OT-II responding T-cells. NS = not sig-
nificant, *p ≤ 0.05, **p ≤ 0.01 determined by paired T-test.
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have revealed that Ptpn22R619W results in enhanced IL-12 production
from BMDC following LPS stimulation. We therefore assessed the se-
cretion of both the IL-12p40 subunit (common to IL-12 and IL-23) and
IL-12p70. However, we observed no significant PTPN22 dependent
difference in the secretion of these factors in the presence or absence of
LPS stimulation (Fig. 5A). Ligation of CD40 on BMDC by CD40L ex-
pressed on activated T-cells results in enhanced BMDC cytokine pro-
duction [18]. To assess if day 6 T-cells from Ptpn22−/− BMDC co-cul-
tures were able to induce enhanced IL-12p40 secretion through CD40
ligation, we measured IL-12p40 secretion in the first 24 h of the sec-
ondary co-culture. Once again, we observed that there was no PTPN22
dependent difference in IL-12p40 secretion (Fig. 5B). In support of this,
no difference in OT-II T-cell surface expression of CD40L was observed
following primary culture with either WT or Ptpn22−/− BMDC
(Fig. 5C). Furthermore, we found that following culture of LPS acti-
vated WT or Ptpn22−/− BMDC on plate bound anti-CD40 no PTPN22
dependent difference in IL-12p40 secretion could be detected (Fig. 5D).
Finally, to assess if any unidentified BMDC secreted factor/s was cap-
able of mediating the enhanced Th1 response following co-culture with
Ptpn22−/− BMDC we performed a conditioned media experiment. OT-II
T-cells were cultured on anti-CD3 and anti-CD28 for 6 days in the
presence or absence of 50% conditioned media from day 6 OT-II T-cell
co-cultures with either WT or Ptpn22−/− BMDCs. However, we also
observed that there was no PTPN22 dependent difference in the gen-
eration of either IFNγ, IL-17 or TNFα+ cells following culture with WT
or Ptpn22−/− conditioned media (Fig. 5E). These data indicated that
the expanded Th1 responses observed in Ptpn22−/− co-cultures were
unlikely to be explained by a DC derived secreted factor.
3.6. DC expression of PTPN22 regulates Th1 differentiation through an
LFA-1 contact dependent mechanism
We next assessed if a contact dependent mechanism may explain
enhanced Th1 responses following co-culture with Ptpn22−/− BMDC.
Fig. 5. Potentiated Th1 responses induced by Ptpn22−/− BMDC are not explained by altered production of a secreted factor. (A) Day 6 WT and Ptpn22−/−
BMDC were pulsed for 24 h in the presence or absence of LPS. Cell free supernatants were assessed for IL-12p40, IL-12p70 and IL-6 by cytokine specific immunoassay.
N=11–15 independent experiments per group. NS= not significant determined by unpaired T-test. (B) Day 6 WT and Ptpn22−/− LPS and OVA323-339 pulsed BMDC
were co-cultured with cell trace violet (CTV) labelled WT CD4+ OT-II T-cells for 24 h and cell free supernatants were assessed for IL-12p40 by immunoassay. N= 6–7
per group with each data point representing an individual WT or Ptpn22−/− BMDC preparation, points are paired by the OT-II responding T-cells. (C) Day 6 WT and
Ptpn22−/− LPS and OVA323-339 pulsed BMDC were co-cultured with CTV labelled WT CD4+ OT-II T-cells for 24 h. Cell surface expression of CD40L on CD3+ CD4+
T-cells was determined by flow cytometry. One representative flow plot of 3 independent experiments; T-cells co-cultured with WT BMDC (dashed line) or Ptpn22−/−
BMDC (solid line) (D) LPS pulsed WT and Ptpn22−/− BMDC were stimulated for 24 h with plate bound anti-CD40 and cell free supernatants were assessed for IL-
12p40 by immunoassay. Data are depicted as in IL-12p40 fold change from PBS control to anti-CD40. N=4 independent experiments; bars represent mean ± s.d.
(E)WT OT-II T-cells were cultured for 6 days on anti-CD3 and ant-CD28 in the presence of 50% conditioned media obtained from day 6 WT or Ptpn22−/− BMDC:WT
OT-II co-cultures. At day 6 of culture in the presence of conditioned media T-cells were restimulated for 6 h with PMA, ionomycin and monensin and the proportion of
CD3+ CD4+ IFNγ+, IL-17+, or TNFα+ cells determined by intracellular flow cytometry. N = 3 independent experiments; bars represent mean ± s.d. NS = not
significant, *p ≤ 0.05, **p ≤ 0.01 determined by unpaired T-test.
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As described above, PTPN22 is a negative regulator of LFA-1 signalling
in T-cells and LFA-1 signalling regulates Th1 responses (Fig. 3). We
hypothesised that enhanced Th1 responses elicited by co-culture with
Ptpn22−/− BMDC might be due in part to enhanced LFA-1 signals.
Firstly, we observed no difference in the cell surface expression of
ICAM-1 (CD54), CD40, CD86 or MHCII on WT or Ptpn22−/− BMDC
following LPS maturation (Fig. 6A and Supplementary Fig. 3A). WT OT-
II T-cells were co-cultured with WT or Ptpn22−/− BMDC (as in Fig. 4)
for 8 days in the presence of either neutralising anti-LFA-1 or isotype
control and the proportion of intracellular IFNγ+ OT-II T-cells assessed.
We observed that in the presence of the isotype control OT-II T-cells co-
cultured with Ptpn22−/− BMDC generated a significantly enhanced
proportion of IFNγ+ cells, as in Fig. 4A (Fig. 6B). Interestingly, we
observed that the enhanced IFNγ+ phenotype conferred by Ptpn22−/−
BMDC was lost when OT-II T-cells were cultured in the presence of anti-
LFA-1 (Fig. 6B), indicating that the difference in co-culture induced Th1
responses may be, at least in part, due to an LFA-1 dependent me-
chanism.
Taken together, our data demonstrate that IFNγ+ CD4+ T-cells are
specifically expanded in vivo with age or following an inflammatory
immune response. Our data indicate that perturbations to ICAM-1-LFA-
1 signalling conferred by the absence of PTPN22 in either T-cells or DCs
potentiates IFNγ secretion by CD4 T-cells, thereby contributing to the
expansion of IFNγ+ CD4+ T-cells observed in vivo.
4. Discussion
Here, we describe how PTPN22 contributes to the expansion of Th1
cells in vivo in aged Ptpn22−/− and Ptpn22619W mice or following a
repeated immune challenge in Ptpn22−/− mice by regulating LFA-1
dependent interactions. We propose that PTPN22 operates in both a T-
cell intrinsic and extrinsic manner to regulate LFA-1 dependent Th1 cell
responses, in turn influencing the overall signalling threshold over time
to promote IFNγ production (A schematic, summarising these me-
chanistic features, is provided in Supplementary Fig. S4.).
As observed in previous investigations, we found that 2-4-month-old
Ptpn22−/− mice have similar proportions of IFNγ+ T-cells, but an ex-
panded repertoire of regulatory T-cells as mice age [14,20]. However,
we noted that as Ptpn22−/− mice age the expansion of regulatory T-
cells coincides with an expansion of Th1 cells. These data indicate that
with aging or following certain types of chronic immune challenge the
balance of the immune response is potentially altered in favour of a
Fig. 6. Ptpn22−/− BMDC promote Th1 responses in an
LFA-1 dependent manner. (A) Day 6 WT and Ptpn22−/−
BMDC were pulsed for 24 h in the presence or absence of
LPS. Cell surface expression of maturation markers was de-
termined by flow cytometry. Median Fluorescent intensity
(MFI) of CD86, CD40, MHCcII IAb, and CD54 (ICAM-1).
N=6–10 independent experiments; bar represents
mean ± s.e.m, NS=not significant determined by un-
paired T-test. (B) Day 6 WT and Ptpn22−/− LPS and OVA323-
339 pulsed BMDC were co-cultured with cell trace violet
(CTV) labelled WT CD4+ OT-II T-cells for 6 days in the
presence or absence of anti-LFA1 or isotype control. At day
6 cells were T-cells were restimulated with a fresh prepara-
tion of WT or Ptpn22−/− BMDC for 48 h and then restimu-
lated for 6 h with PMA, ionomycin and monensin and the
proportion of CD3+ CD4+ IFNγ+ or TNFα+ cells was de-
termined by intracellular flow cytometry. N = 4 in-
dependent experiments; bar represents mean ± s.d,
NS = not significant, *p≤ 0.05, determined by unpaired T-
test.
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more inflammatory phenotype. The onset of many autoimmune dis-
eases tends to occur in the 5th-6th decades of life [25]. Therefore, our
data may provide some explanation as to how perturbations to PTPN22
promote autoimmunity later in life, following an alteration of ICAM-1-
LFA-1 responsiveness over time, which accumulates to promote the
expansion of inflammatory IFNγ responses with aging.
Although we observed that CD3/CD28 mediated induction of CD4+
Th1 responses are intact in Ptpn22−/− T-cells even under conditions of
low avidity stimulation [14], we cannot exclude the possibility that
under conditions of low affinity TCR stimulation CD4+ Th1 responses
may also be regulated in a similar manner to CD8+ T-cells activated
with low affinity altered peptide ligands [13]. An important finding was
that anti-CD3 and LFA-1 stimulation of Ptpn22−/− T-cells leads to in-
creased IFNγ responses. These data correlated with an enhanced ability
of Ptpn22−/− T-cell LFA-1 to engage ICAM-1, which manifests down-
stream through increased T cell-DC conjugates. Our data indicate that
PTPN22 acts as a phosphatase that fine-tunes T-cell immune synapse
signals with functionally important consequences. Multiple studies
have demonstrated that perturbations to PTPN22 can alter the balance
of the immune response. For example, overexpression of PTPN22 re-
sulted in attenuated Th1 differentiation at low strength TCR stimulation
and protected mice from a model of diabetes [27]. Further studies have
demonstrated that PTPN22 is capable of regulating the Th17 bias in
mannan immunised SKG mice towards a Th1/Treg phenotype, pro-
tecting the mice from arthritis [16]. Although Ptpn22−/− mice on the
C57BL/6 background do not spontaneously develop autoimmunity (due
to the enhanced immunosuppressive function of expanded regulatory T
cells), our data indicate that over time there is a concomitant expansion
in Th1 cells. The expansion of Th1 cells in order to overcome the im-
munosuppressive capabilities of Ptpn22−/− regulatory T-cells is likely
to be a crucial checkpoint beyond which autoimmune disease becomes
manifest.
Recent studies have indicated that PTPN22 also indirectly regulates
T-cell responses via regulation of antigen presenting cell function. Here,
we observed that PTPN22 regulates BMDC induced Th1 responses via a
contact dependent mechanism, which most likely occurs, at least in
part, via ICAM-1-LFA-1 engagement. Similar to our previous in-
vestigation [26], but in contradiction to a study assessing BMDC from
Ptpn22619W mice [10], PTPN22 was not found to regulate LPS induced
expression of cell surface maturation markers or secreted cytokines by
BMDC. The reasons for these discrepancies may point to the subtle role
that PTPN22 plays in fine tuning signalling thresholds, such that dif-
ferences in stimulation dosing modulates if, and how, PTPN22 regulates
a signalling cascade. Indeed, our data indicate that PTPN22 regulates
LPS matured BMDC induced Th1 induction only over multiple rounds of
T-cell stimulation; potentially offering an explanation as to why ex-
panded Th1 responses occur only with aging or over long durations of
immune challenge.
The data presented here are limited to murine Ptpn22−/− and
Ptpn22619W models. However, recent investigations indicate that
common pathways operate between species. Supplementary Table 1
highlights studies reported to date that have assessed how the murine
and human PTPN22 variants regulate Th1/LFA-1 responses. The evi-
dence indicates that in both mouse and man IFNγ+ T-cells are ex-
panded, though the conditions through which expansion is observed
may differ. Several groups have reported an association between the
PTPN22-620W variant, increased pErk signalling and IFNγ expression
[5,28,29]; our murine data provides new mechanistic insights as to how
this may be occurring in man.
5. Conclusions
Here we provide evidence to suggest that PTPN22 negatively reg-
ulates LFA-1 dependent production of IFNγ producing Th1 cells via T-
cell intrinsic and extrinsic mechanisms. These data indicate that
PTPN22 plays important role in regulating the thresholds of signalling
as immune responses mature over time and the impact that this could
confer on the resulting immune response.
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